Diabetic retinopathy

Variations in patient therapeutic outcomes and pharmacogenomics

Aniruddha Agarwal, Mohamed K. Soliman, Yasir J. Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Diabetes and its microvascular complications in patients poses a significant challenge and constitutes a major health problem. When it comes to manifestations in the eye, each case of diabetic retinopathy (DR) is unique, in terms of the phenotype, genotype, and, more importantly, the therapeutic response. It is therefore important to identify factors that distinguish one patient from another. Personalized therapy in DR is a new trend aimed at achieving maximum therapeutic response in patients by identifying genotypic and phenotypic factors that may result in less than optimal response to conventional therapy, and consequently, lead to poorer outcome. With advances in the identification of these genetic markers, such as gene polymorphisms and human leucocyte antigen associations, as well as development of drugs that can target their effects, the future of personalized medicine in DR is promising. In this comprehensive review, data from various studies have been analyzed to present what has been achieved in the field of pharmacogenomics thus far. An insight into future research is also provided.

Original languageEnglish (US)
Pages (from-to)399-409
Number of pages11
JournalPharmacogenomics and Personalized Medicine
Volume7
DOIs
StatePublished - Dec 12 2014

Fingerprint

Pharmacogenetics
Diabetic Retinopathy
Eye Manifestations
Precision Medicine
Therapeutics
HLA Antigens
Genetic Markers
Genotype
Phenotype
Health
Pharmaceutical Preparations
Genes

Keywords

  • Genomic markers
  • Genotype
  • Linkage
  • Mutation
  • Personalized medicine
  • Phenotype
  • Polymorphism
  • Responder
  • Therapeutic variation
  • VEGF mutation

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Diabetic retinopathy : Variations in patient therapeutic outcomes and pharmacogenomics. / Agarwal, Aniruddha; Soliman, Mohamed K.; Sepah, Yasir J.; Do, Diana V.; Nguyen, Quan Dong.

In: Pharmacogenomics and Personalized Medicine, Vol. 7, 12.12.2014, p. 399-409.

Research output: Contribution to journalReview article

Agarwal, Aniruddha ; Soliman, Mohamed K. ; Sepah, Yasir J. ; Do, Diana V. ; Nguyen, Quan Dong. / Diabetic retinopathy : Variations in patient therapeutic outcomes and pharmacogenomics. In: Pharmacogenomics and Personalized Medicine. 2014 ; Vol. 7. pp. 399-409.
@article{90979265ec764b9d90cdf5ccc94c9c21,
title = "Diabetic retinopathy: Variations in patient therapeutic outcomes and pharmacogenomics",
abstract = "Diabetes and its microvascular complications in patients poses a significant challenge and constitutes a major health problem. When it comes to manifestations in the eye, each case of diabetic retinopathy (DR) is unique, in terms of the phenotype, genotype, and, more importantly, the therapeutic response. It is therefore important to identify factors that distinguish one patient from another. Personalized therapy in DR is a new trend aimed at achieving maximum therapeutic response in patients by identifying genotypic and phenotypic factors that may result in less than optimal response to conventional therapy, and consequently, lead to poorer outcome. With advances in the identification of these genetic markers, such as gene polymorphisms and human leucocyte antigen associations, as well as development of drugs that can target their effects, the future of personalized medicine in DR is promising. In this comprehensive review, data from various studies have been analyzed to present what has been achieved in the field of pharmacogenomics thus far. An insight into future research is also provided.",
keywords = "Genomic markers, Genotype, Linkage, Mutation, Personalized medicine, Phenotype, Polymorphism, Responder, Therapeutic variation, VEGF mutation",
author = "Aniruddha Agarwal and Soliman, {Mohamed K.} and Sepah, {Yasir J.} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2014",
month = "12",
day = "12",
doi = "10.2147/PGPM.S52821",
language = "English (US)",
volume = "7",
pages = "399--409",
journal = "Pharmacogenomics and Personalized Medicine",
issn = "1178-7066",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Diabetic retinopathy

T2 - Variations in patient therapeutic outcomes and pharmacogenomics

AU - Agarwal, Aniruddha

AU - Soliman, Mohamed K.

AU - Sepah, Yasir J.

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2014/12/12

Y1 - 2014/12/12

N2 - Diabetes and its microvascular complications in patients poses a significant challenge and constitutes a major health problem. When it comes to manifestations in the eye, each case of diabetic retinopathy (DR) is unique, in terms of the phenotype, genotype, and, more importantly, the therapeutic response. It is therefore important to identify factors that distinguish one patient from another. Personalized therapy in DR is a new trend aimed at achieving maximum therapeutic response in patients by identifying genotypic and phenotypic factors that may result in less than optimal response to conventional therapy, and consequently, lead to poorer outcome. With advances in the identification of these genetic markers, such as gene polymorphisms and human leucocyte antigen associations, as well as development of drugs that can target their effects, the future of personalized medicine in DR is promising. In this comprehensive review, data from various studies have been analyzed to present what has been achieved in the field of pharmacogenomics thus far. An insight into future research is also provided.

AB - Diabetes and its microvascular complications in patients poses a significant challenge and constitutes a major health problem. When it comes to manifestations in the eye, each case of diabetic retinopathy (DR) is unique, in terms of the phenotype, genotype, and, more importantly, the therapeutic response. It is therefore important to identify factors that distinguish one patient from another. Personalized therapy in DR is a new trend aimed at achieving maximum therapeutic response in patients by identifying genotypic and phenotypic factors that may result in less than optimal response to conventional therapy, and consequently, lead to poorer outcome. With advances in the identification of these genetic markers, such as gene polymorphisms and human leucocyte antigen associations, as well as development of drugs that can target their effects, the future of personalized medicine in DR is promising. In this comprehensive review, data from various studies have been analyzed to present what has been achieved in the field of pharmacogenomics thus far. An insight into future research is also provided.

KW - Genomic markers

KW - Genotype

KW - Linkage

KW - Mutation

KW - Personalized medicine

KW - Phenotype

KW - Polymorphism

KW - Responder

KW - Therapeutic variation

KW - VEGF mutation

UR - http://www.scopus.com/inward/record.url?scp=84919764158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919764158&partnerID=8YFLogxK

U2 - 10.2147/PGPM.S52821

DO - 10.2147/PGPM.S52821

M3 - Review article

VL - 7

SP - 399

EP - 409

JO - Pharmacogenomics and Personalized Medicine

JF - Pharmacogenomics and Personalized Medicine

SN - 1178-7066

ER -